Vaccines targeting TAAs have demonstrated non-improved overall survival in phase III trials for pancreatic cancer (Middleton et al., 2014) and renal cell carcinoma (Rini et al., 2016), but the use of a peptide vaccine against three TAAs (EphA2, IL13Rα2, and survivin) in children with recurrent high-grade gliomas was well tolerated and demonstrated a median PFS at 4.1 months and median OS at 12.9 months (Pollack et al., 2016). This evidence concerns the gene IL13RA2 and central nervous system cancer.